NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

And 3 months improvement in OS over SOC has been enough to get other treatments approved.

3 months is the mean improvement in OS and the most immunocompromised patients got no benefit hence the average benefit of those who did get any benefit from DcVax was likely 6 months as demonstrated in the 24, 36 and 60 month survival statistics. Even those who did not make it to the 5-year mark still got to spend significantly more time with their families than they could have expected from their GBM diagnosis on SOC. With the right combination of treatments, signs are that many more will survive 5 years or longer.